Table 1 Demographics, clinical profiles, and neuroimaging data of patients with HFM and HC
From: The cerebellum is associated with 2-year prognosis in patients with high-frequency migraine
|  | HC (n = 37) | HFM (n = 56) | HFM Good outcome (n = 37) | HFM Poor outcome (n = 19) |
|---|---|---|---|---|
Age | 39.4 ± 9.3 | 40.3 ± 10.5 | 40.8 ± 11.1 | 39.4 ± 9.6 |
Sex (F/M) | 27/10 | 43/13 | 27/10 | 16/3 |
Aura (%) | nil | 9 (16%) | 7 (18.9%) | 2 (10.5%) |
Headache frequency-baseline (d/m) | nil | 19.2 ± 7.1 | 18.9 ± 7.1 | 19.7 ± 7.4 |
Chronic migraine | nil | 44 (78.6%) | 29 (78.4%) | 15 (78.9%) |
Disease duration (years) | nil | 17.2 ± 11.3 | 15.7 ± 10.2 | 20.1 ± 13.0 |
Headache intensity (NRS 0–10) | nil | 6.5 ± 1.7 | 6.6 ± 1.7 | 6.3 ± 2.0 |
MIDAS | nil | 43.9 ± 49.0 | 20 ± 50 | 62.5 ± 92 |
HADS-A | 4.7 ± 2.5# | 8.9 ± 4.3 | 9.1 ± 4.3 | 8.5 ± 4.3 |
HADS-D | 3.5 ± 2.8# | 6.8 ± 5.0 | 6.7 ± 5.5 | 6.8 ± 4.2 |
Prophylactic drugs use | nil | 48 (85.7%) | 30 (81.1%) | 18 (94.7%) |
Prophylactic drugs use at 2-year follow-up | nil | 16 (28.6%) | 10 (27%) | 6 (31.6%) |
Headache frequency at 2-year follow-up (d/m) | nil | 9.0 ± 9.5 | 3.3 ± 2.4* | 20.3 ± 7.8 |
TIV (mm3) | 1430.8 ± 129.6 | 1399.8 ± 132.5 | 1404.7 ± 124.6 | 1390.2 ± 149.7 |